Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesMiscellaneous Medical ServicesHCPCS hcpcs-m0233-tocilizumab-infusion-covid19-hospitalized-adults
    Ask Trek AI about this page

    HCPCS Level II M0233: Tocilizumab-aazg IV Infusion, First Dose

    HCPCS Level II code M0233 describes the first-dose intravenous infusion and post-administration monitoring for tocilizumab-aazg given to hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation; service type: therapeutic monoclonal antibody infusion, typical site of service: inpatient hospital (acute care) setting with monitored infusion capability.

    For related coverage guidance, see recent payer policy updates: Skilled Nursing and Skilled Rehabilitation Services (Outpatient), Habilitation and Rehabilitation Therapy (Occupational, Physical, and Speech) (for New Mexico Only), Physical Therapy/Medicine Corporate Medical Policy.

    Customize your policy alerts

    Sign up for hcpcs M0233 policy alerts

    Get alerted when payer policies referencing M0233 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 67-year-old hospitalized patient with severe COVID-19 presents with progressive hypoxemic respiratory failure. The patient is receiving systemic corticosteroids and requires supplemental oxygen via high-flow nasal cannula. The treating team determines the patient meets criteria for immunomodulatory therapy with tocilizumab. After informed consent, the pharmacy verifies weight-based dosing for M0233 (first dose), the nursing team places a peripheral or central IV line, and the infusion is prepared under aseptic technique. The infusion is administered with continuous monitoring of vital signs during the infusion and for a period afterward to observe for infusion reactions and clinical response. Laboratory monitoring (including CBC, liver enzymes, and inflammatory markers) is obtained before and after administration per institutional protocol. If the patient progresses to non-invasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO), documentation reflects ongoing need for supplemental oxygen and systemic corticosteroid therapy to support billing under M0233.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hourMay be used for other IV infusions given before or after the tocilizumab infusion when billed separately
    96366Each additional hour (list separately in addition to code for primary infusion)When the infusion duration extends beyond the initial hour and payer allows separate reporting
    36415Collection of venous blood by venipuncturePerformed before infusion for baseline labs (CBC, CMP, liver enzymes)
    99223Initial hospital care, typically 70 minutes or moreHospitalist or intensivist initial admission evaluation for a critically ill patient who will receive M0233
    93000Electrocardiogram, routine ECG with at least 12 leads; tracing and interpretationPerformed when cardiac monitoring or baseline ECG is clinically indicated prior to immunomodulatory therapy

    Related Modifiers

    6 rows

    ModifierDescriptionWhen to Use
    25CPT modifier 25 indicates that on the same day as another procedure or service, the same physician or other qualified health care professional provided a significant, separately identifiable…- When to apply: Use modifier 25 only on an E/M code to indicate the same provider delivered a significant, separately identifiable E/M service on the same day as another procedure or service — i.e.,…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    76Modifier -76, Repeat Procedure or Service by Same Physician or Other Qualified Health Care Professional, is appended when the same provider performs an identical, medically necessary procedure or…- Use modifier -76 when the same physician or other qualified health care professional performs an identical procedure or service a second (or subsequent) time on the same date of service and the…
    77Modifier 77 indicates that a previously performed procedure or service was legitimately repeated by a different physician or other qualified health care professional. The AMA’s CPT definition…- Use modifier 77 when a basic procedure or service already performed is repeated by a different physician or other qualified health care professional (for example, a second provider independently…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207RC0000X
    2084P0800X
    207K00000X
    207L00000X
    163W00000X
    335V00000X
    202D00000X
    2279P1006X

    Related ICD-10-CM Codes

    25 rows

    ICD-10-CM CodeDescription
    A41.89Other specified sepsis
    A41.9Sepsis, unspecified organism
    B34.2Coronavirus infection, unspecified
    E11.9Type 2 diabetes mellitus without complications
    E87.1Hypo-osmolality and hyponatremia
    I46.9Cardiac arrest, cause unspecified
    I50.9Heart failure, unspecified
    J12.82Pneumonia due to coronavirus disease 2019
    J12.89Other viral pneumonia
    J18.9Pneumonia, unspecified organism

    Showing 1–10 of 25

    Related Payer Policy Updates

    Specialty: Physical Medicine, Rehab & Therapies1 / 3

    10 rows

    PolicyPayerEffective Date
    Skilled Nursing and Skilled Rehabilitation Services (Outpatient)Anthem2026-10-01
    Habilitation and Rehabilitation Therapy (Occupational, Physical, and Speech) (for New Mexico Only)UnitedHealthcare2026-10-01
    Physical Therapy/Medicine Corporate Medical Policybcbsvermont2026-10-01
    Speech Language Pathology/Therapy Services Corporate Medical Policybcbsvermont2026-10-01
    Cognitive Rehabilitation Corporate Medical Policybcbsvermont2026-10-01
    Occupational Therapy Corporate Medical Policybcbsvermont2026-10-01
    Biomagnetic TherapyConnectiCare2026-09-11
    Habilitation and Rehabilitation Therapy (Occupational, Physical, and Speech) (for Idaho Only)UnitedHealthcare2026-09-01
    Rehabilitation Services (Physical, Occupational, and Speech Therapy)UnitedHealthcare2026-09-01
    Manipulative Therapy (for Tennessee Only)UnitedHealthcare2026-09-01

    Related Codes

    HCPCS-M0075-CELLULAR-THERAPY-PROCESSING-PROVISION

    HCPCS Level II M0075: Cellular Therapy

    HCPCS-M0076-PROLOTHERAPY-INJECTION-THERAPY

    HCPCS Level II M0076: Prolotherapy

    HCPCS-M0100-INTRAGASTRIC-HYPOTHERMIA-GASTRIC-FREEZING

    HCPCS Level II M0100: Intragastric Hypothermia (Gastric Freezing)

    HCPCS-M0201-IN-HOME-VACCINE-ADMINISTRATION

    HCPCS Level II M0201: In-Home Vaccine Administration

    HCPCS-M0220-TIXAGEVIMAB-CILGAVIMAB-PRE-EXPOSURE-PROPHYLAXIS

    HCPCS Level II M0220: Tixagevimab and Cilgavimab Pre-Exposure Prophylaxis

    HCPCS-M0221-TIXAGEVIMAB-CILGAVIMAB-PRE-EXPOSURE-PROPHYLAXIS-HOME-ADMINISTRATION

    HCPCS M0221: Tixagevimab and Cilgavimab Pre-Exposure Prophylaxis

    HCPCS-M0222-BEBTELOVIMAB-INTRAVENOUS-INJECTION-MONITORING

    HCPCS Level II M0222: Bebtelovimab Intravenous Injection with Monitoring

    HCPCS-M0223-BEBTELOVIMAB-INTRAVENOUS-INJECTION-HOME-MONITORING

    HCPCS M0223: Intravenous Bebtelovimab with Home Monitoring

    HCPCS-M0224-PEMIVIBART-PRE-EXPOSURE-PROPHYLAXIS-INFUSION

    HCPCS M0224: Pemivibart Intravenous Infusion for Pre-Exposure Prophylaxis

    HCPCS-M0234-TOCILIZUMAB-INFUSION-HOSPITALIZED-COVID19

    HCPCS Level II M0234: Tocilizumab Infusion for Hospitalized Adults with COVID-19

    Showing 1–10 of 27

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.